A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT04887857
- Locations
- 🇺🇸
Local Institution - 105, Boston, Massachusetts, United States
🇺🇸Local Institution - 102, Cleveland, Ohio, United States
🇦🇺Local Institution - 201, Melbourne, Australia
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 174
- Registration Number
- NCT04884035
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Local Institution - 501, Adelaide, South Australia, Australia
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Registration Number
- NCT04882163
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT04860466
- Locations
- 🇫🇷
Local Institution - UNK-5, Angers, France
🇫🇷Local Institution - 303, Lille, France
🇫🇷Local Institution - 302, Montpellier CEDEX 5, France
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 312
- Registration Number
- NCT04855136
- Locations
- 🇺🇸
Local Institution - 109, Hackensack, New Jersey, United States
🇺🇸Local Institution - 114, Chicago, Illinois, United States
🇺🇸Local Institution - 108, Boston, Massachusetts, United States
A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT04839809
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Celgene
- Target Recruit Count
- 221
- Registration Number
- NCT04800315
- Locations
- 🇺🇸
Local Institution - 125, Silver Spring, Maryland, United States
🇨🇦Dr. Chih-ho Hong Medical Inc., Surrey, British Columbia, Canada
🇨🇦Local Institution - 213, Edmonton, Alberta, Canada
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 80
- Registration Number
- NCT04789655
- Locations
- 🇫🇷
Local Institution - 301, Pessac Cedex, France
🇫🇷Local Institution - 304, Paris, France
🇫🇷Local Institution - 302, Villejuif CEDEX, France
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
- Conditions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Celgene
- Registration Number
- NCT04771078
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 430
- Registration Number
- NCT04753697
- Locations
- 🇺🇸
Local Institution - 130, Beavercreek, Ohio, United States
🇺🇸Local Institution - 144, Birmingham, Alabama, United States
🇺🇸Local Institution - 158, Tuscaloosa, Alabama, United States